43

ANA-12

43 Publications Verification

Cat. No.: HY-12497

CAS No.: 219766-25-3

Purity: 99.90%

Target:

Trk Receptor NOD-like Receptor (NLR) AIM2 Caspase

Research Areas:

Neurological Disease Inflammation/Immunology

ANA-12 is a brain-penetrant, selective TrkB antagonist with IC₅₀ values of 45.6 nM and 41.1 μM, and K_d values of 10 nM and 12 μM, for high- and low-affinity sites, respectively. ANA-12 specifically inhibits BDNF-induced TrkB receptor activation and its downstream signaling cascades by directly and non-competitively binding to the TrkB receptor, without affecting the functions of TrkA and TrkC. ANA-12 is used in research concerning neuropsychiatric disorders (such as depression and anxiety), acute and chronic pain, neuroimmune inflammation, and the mechanisms of learning and memory .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

20

Rolipram

20 Cited Publications

Cat. No.: HY-16900

CAS No.: 61413-54-5

Synonyms: (R,S)-Rolipram; (±)-Rolipram; ZK 62711

Target:

Bacterial HIV Phosphodiesterase (PDE) Epigenetic Reader Domain Amyloid-β

Research Areas:

Infection Neurological Disease Cancer

Rolipram is a PDE4 inhibitor, with blood-brain barrier permeability, that reverses β-amyloid-induced learning and memory impairment in rats. Rolipram elevates intracellular cAMP and clevels and regulates the cAMP/CREB signaling pathway, thereby alleviating neuroinflammation and apoptotic responses. Rolipram promotes neuronal differentiation of human bone marrow mesenchymal stem cells and inhibits Methamphetamine- and morphine-induced hyperlocomotion in mice. Rolipram also reduces the viability of glioblastoma stem-like cells and enhances Bevacizumab (HY-P9906)-induced cell death. Rolipram inhibits the expression of proinflammatory cytokines and enhances central noradrenergic transmission. Rolipram is mainly used in studies related to various central nervous system diseases including Alzheimer's disease, major depressive disorder, glioblastoma multiforme, and multiple sclerosis .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

5

Quinpirole

5 Cited Publications

Cat. No.: HY-B1752

CAS No.: 80373-22-4

Synonyms: LY 171555; (-)-LY 141865

Target:

Dopamine Receptor Calcium Channel Bcl-2 Family iGluR Apoptosis

Research Areas:

Neurological Disease

Quinpirole (LY 171555; (-)-LY 141865) is a D2/D3 dopamine receptor agonist and a CaV1.3 calcium channel modulator. Quinpirole normalizes dendritic spine density in dopamine-depleted striatum, upregulates the protein expression of BCL2 and GluR2, downregulates the protein expression of BAX, and delays the onset of seizures. Quinpirole enhances learning and memory, inhibits neuronal apoptosis (apoptosis), and induces anxiety-like, stereotyped, and compulsive behaviors. Quinpirole disrupts prepulse inhibition in rhesus monkeys, enhances the activity of paraventricular thalamic neurons to promote recovery from Isoflurane anesthesia, and alters the composition of the gut microbiota in rats. Quinpirole can be used in research related to dyskinesia, pain, epilepsy, and neurological disorders including anxiety disorder, obsessive-compulsive disorder, and schizophrenia .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

2

WAY-267464

2 Cited Publications

Cat. No.: HY-15522

CAS No.: 847375-16-0

Target:

Oxytocin Receptor

Research Areas:

Neurological Disease

WAY-267464 is a non-peptide oxytocin receptor (OTR) agonist. WAY-267464 can impair social recognition memory in rats through a vasopressin 1A receptor antagonist action. WAY-267464 can be used for the research of psychiatric disorders, such disorders include autism spectrum disorder, schizophrenia, and social anxiety disorder .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

2

TAK-418

2 Cited Publications

Cat. No.: HY-138830

CAS No.: 1818252-53-7

Purity: 99.81%

Target:

Histone Demethylase

Research Areas:

Neurological Disease

TAK-418 is an orally active, blood-brain barrier-penetrant LSD1 inhibitor with a human IC₅₀ of 2.9 nM. TAK-418 irreversibly inhibits LSD1 by forming a compact flavin-FAD adduct with the catalytic domain FAD, blocking the demethylation of H3K4me1/2 and H3K9me1/2 without disrupting the LSD1-GFI1B interaction. TAK-418 restores normally dysregulated brain gene expression and DNA methylation, increases H3K4me1/2/3 and H3K9me2 at the Ucp2 locus, and induces Ucp2 mRNA expression. TAK-418 rescues defective H3K4 histone modifications, normalizes adult neurogenesis, and improves recognition memory, social behavior, and cognition in rodent models. TAK-418 can be used in research related to neurodevelopmental disorders, Alzheimer's disease, and autism spectrum disorders .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

2

WAY-267464 hydrochloride

2 Cited Publications

Cat. No.: HY-108679

CAS No.: 1432043-31-6

Target:

Oxytocin Receptor

Research Areas:

Neurological Disease

WAY-267464 (hydrochloride) is a non-peptide oxytocin receptor (OTR) agonist. WAY-267464 (hydrochloride) can impair social recognition memory in rats through a vasopressin 1A receptor antagonist action. WAY-267464 (hydrochloride) can be used for the research of psychiatric disorders, such disorders include autism spectrum disorder, schizophrenia, and social anxiety disorder .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

1

Melanotan (MT)-II

1 Cited Publications

Cat. No.: HY-P0267

CAS No.: 121062-08-6

Target:

Melanocortin Receptor

Research Areas:

Neurological Disease Metabolic Disease Endocrinology

Melanotan (MT)-II is a melanocortin receptor agonist. Melanotan (MT)-II activates melanocortin receptor 3 and melanocortin receptor 4, and stimulates the release of central endogenous oxytocin. Melanotan (MT)-II reverses recognition memory impairment, increased anxiety levels and reduced exploratory tendency in zebrafish exposed to short-term high-fat diet. Melanotan (MT)-II improves impaired social behavior indicators in mouse models of autism spectrum disorder. Melanotan (MT)-II induces weight loss, reduces food intake and exerts anorectic effects. Melanotan (MT)-II increases intracavernous pressure and erectile activity in brown rats. Melanotan (MT)-II can be used in studies related to memory impairment, anxiety, reduced exploratory behavior, autism spectrum disorder, obesity and erectile dysfunction .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

1

RO-275

1 Cited Publications

Cat. No.: HY-160505

CAS No.: 2648837-04-9

Target:

HCN Channel

Research Areas:

Neurological Disease

RO-275 (compound 29) is a potent, selective and orally active HCN1 inhibitor with IC₅₀ values of 0.046, 14.3, 4.6, 13.9 µM for HCN1, HCN2, HCN3, HCN4, respectively. RO-275 rescues decremented working memory. RO-275 has the potential for the research of cognitive dysfunction in brain disorder .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

1

Osoresnontrine

1 Cited Publications

Cat. No.: HY-112831

CAS No.: 1189767-28-9

Purity: 99.88%

Synonyms: BI-409306

Target:

Phosphodiesterase (PDE)

Research Areas:

Neurological Disease

Osoresnontrine (BI-409306) is a potent and selective PDE9A inhibitor, with an IC₅₀ of 52 nM, and shows weak activity against other PDEs, such as PDE1A (IC₅₀, 1.4 µM), PDE1C (IC₅₀, 1.0 µM), PDE2A, PDE3A, PDE4B, PDE5A, PDE6AB, PDE7A, and PDE10A (IC₅₀ all > 10 μM); Osoresnontrine can be used in the research of memory enhancement in CNS disorders.

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

1

S 17092

1 Cited Publications

Cat. No.: HY-15114

CAS No.: 176797-26-5

Purity: 99.78%

Synonyms: S 17092-1

Target:

Prolyl Endopeptidase (PREP) Apoptosis

Research Areas:

Neurological Disease

S 17092 (S 17092-1) is an orally active cerebral prolyl-endopeptidase (PEP) inhibitor with an IC₅₀ of 1.2 nM. S 17092 inhibits cell apoptosis. S 17092 mechanism of action is to inhibit the activity of PEP, slowing down the degradation of neuroactive peptides and thus enhancing memory function. S 17092 can be used for the research of memory impairment and cognitive disorders associated with cerebral aging .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

Osavampator

Cat. No.: HY-115864

CAS No.: 1358751-06-0

Purity: 99.89%

Synonyms: TAK-653; NBI-1065845

Target:

iGluR Lipoxygenase

Research Areas:

Neurological Disease

Osavampator (TAK-653) is a AMPA receptor positive allosteric modulator. Osavampator selectively binds to AMPA-R in a glutamate-dependent manner and induces Ca2+ influx in hGluA1i CHO cells (EC₅₀ = 3.3 μM). Osavampator improves learning and memory in many models. Osavampator is can be used for the research of depressive disorders .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

Docosahexaenoic acid (Standard)

Cat. No.: HY-B2167R

CAS No.: 6217-54-5

Synonyms: DHA (Standard); Cervonic acid (Standard)

Category:

Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Disease markers Endogenous metabolite Cardiovascular System Disorder

Target:

Reference Standards Endogenous Metabolite

Docosahexaenoic acid (Standard) is the analytical standard of Docosahexaenoic acid. This product is intended for research and analytical applications. Docosahexaenoic Acid (DHA) is an omega-3 fatty acid abundantly present brain and retina. It can be obtained directly from fish oil and maternal milk. In Vitro: Docosahexaenoic acid (DHA) is essential for the growth and functional development of the brain in infants. DHA is also required for maintenance of normal brain function in adults. The inclusion of plentiful DHA in the diet improves learning ability and memory . DHA is an essential requirement in every step of brain development like neural cell proliferation, migration, differentiation, synaptogenesis. The multiple double bonds and unique structure allow DHA to impart special membrane characteristics for effective cell signaling. Many development disorders like dyslexia, autism spectrum disorder, attention deficit hyperactivity disorder, schizophrenia etc. are causally related to decreased level of DHA . DHA is a potent RXR ligand inducing robust RXR activation already at low micro molar concentrations. The EC₅₀ for RXRα activation by DHA is about 5-10 μM fatty acid . In Vivo: Docosahexaenoic acid administration over 10 weeks significantly reduces the number of reference memory errors, without affecting the number of working memory errors, and significantly increases the docosahexaenoic acid content and the docosahexaenoic acid/arachidonic acid ratio in both the hippocampus and the cerebral cortex . DHA treatment exerts neuroprotective actions on an experimental mouse model of PD. There is a decrease tendency in brain lipid oxidation of MPTP mice but it does not significantly .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

Etiracetam

Cat. No.: HY-B0106A

CAS No.: 33996-58-6

Synonyms: UCB 6474

Target:

Drug Derivative

Research Areas:

Neurological Disease

Etiracetam is a racetam-class nootropic agent. Etiracetam enhances learning and memory in both normal and amnesic rats. Etiracetam can be used in studies related to memory retrieval disorders and amnesic diseases such as Alzheimer's disease .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

IDRA 21

Cat. No.: HY-101528

CAS No.: 22503-72-6

Purity: 99.33%

Target:

iGluR

Research Areas:

Neurological Disease

IDRA 21 is a positive and orally active modulator of the AMPA receptor. IDRA 21 facilitates excitatory neurotransmission via GluR1/2 receptors. IDRA 21 has the potential for the research of cognitive/memory disorders, including those associated with aging .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

MT-110

Cat. No.: HY-175188

CAS No.: 2404652-82-8

Synonyms: BPN-0027490

Target:

Myosin

Research Areas:

Neurological Disease

MT-110 (BPN-0027490) is a non-muscle myosin NMIIB-selective inhibitor with high brain penetration and favorable safety profile. MT-110 specifically disrupts NMIIB-dependent actin dynamics in dendritic spines, while it exerts no significant adverse effects on cardiac myosin II and cardiac functions (such as cardiac output and heart rate) at tested concentrations. A single administration of MT-110 produces long-lasting (sustained for several weeks) blockade of methamphetamine motivation associated with environmental cues. MT-110 exhibits extremely high specificity, with no interference with cocaine motivation, hippocampus-dependent memory, fear memory, or locomotor and anxiety-like behaviors. MT-110 serves as a valuable tool compound for investigating the mechanisms of methamphetamine use disorder .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

JNJ-55511118

Cat. No.: HY-118424

CAS No.: 2036081-86-2

Target:

iGluR

Research Areas:

Neurological Disease Metabolic Disease

JNJ-55511118 is a selective TARP γ-8 binding AMPA receptor modulator with oral bioavailability and blood-brain barrier permeability, with a K_i of 26 nM. JNJ-55511118 reduces voluntary intake of sweetened alcohol in male mice. In rodent models, JNJ-55511118 inhibits hippocampal neurotransmission, reduces specific electroencephalogram frequency bands, induces transient hyperlocomotion, impairs learning and memory abilities, and exerts anticonvulsant effects. JNJ-55511118 is applicable to research related to alcohol use disorder and seizures .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

Alogabat

Cat. No.: HY-132806

CAS No.: 2230009-48-8

Purity: 99.93%

Synonyms: RG-7816; RO-7017773

Target:

GABA Receptor

Research Areas:

Neurological Disease

Alogabat is a positive allosteric modulator (PAM) and agonist (K_i <100 nM) of the GABAA α5 receptor, targeting the α5β3γ2 subunit with a Ki of 8.7 nM. Alogabat increases the expression level of α5β3γ2 in oocytes (1.97-fold). GABAA has been implicated in cognitive impairment associated with central nervous system (CNS) disorders, brain cancer (including brain tumors such as medulloblastoma), and can be used in the study of mild cognitive impairment (MCI), amnestic MCI (aMCI), age-associated memory impairment (AAMI), age-related cognitive decline (ARCD), dementia, Alzheimer's disease (AD), prodromal AD, post-traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cognitive impairment associated with cancer treatment, mental retardation, Parkinson's disease (PD), autism spectrum disorder, fragile X, Rett syndrome, obsessive-compulsive behavior, and substance addiction .

Compare

loading...